| Nov 15 |
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit
|
| Nov 15 |
AC Immune reports interim results from Phase 2 trial of ACI-7104.056
|
| Nov 14 |
AC Immune stock jumps 20% on data for Parkinson's disease drug
|
| Nov 14 |
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
|
| Nov 13 |
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
|
| Nov 9 |
AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates
|
| Nov 5 |
AC Immune: Q3 Earnings Snapshot
|
| Nov 5 |
AC Immune GAAP EPS of CHF0.05, revenue of CHF25.4M
|
| Nov 5 |
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
|
| Oct 28 |
AC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29%
|
